These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12595463)

  • 41. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Hegerle N; Choi M; Sinclair J; Amin MN; Ollivault-Shiflett M; Curtis B; Laufer RS; Shridhar S; Brammer J; Toapanta FR; Holder IA; Pasetti MF; Lees A; Tennant SM; Cross AS; Simon R
    PLoS One; 2018; 13(9):e0203143. PubMed ID: 30188914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K; Goldberg JB; Pier GB
    Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103.
    Kintz E; Scarff JM; DiGiandomenico A; Goldberg JB
    J Bacteriol; 2008 Apr; 190(8):2709-16. PubMed ID: 18065548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
    Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
    Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.
    Shaikh MOF; Schaefers MM; Merakou C; DiBlasi M; Bonney S; Liao T; Zurakowski D; Kehl M; Tabor DE; DiGiandomenico A; Priebe GP
    Infect Immun; 2022 Oct; 90(10):e0020322. PubMed ID: 36069593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.
    Cryz SJ; Fürer E; Germanier R
    Infect Immun; 1984 Mar; 43(3):795-9. PubMed ID: 6698608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunity and vaccine development in Pasteurella multocida infections.
    Adler B; Chancellor R; Homchampa P; Hunt M; Ruffolo C; Strugnell R; Wapling D
    J Biotechnol; 1996 Jan; 44(1-3):139-44. PubMed ID: 8717397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
    Wu W; Huang J; Duan B; Traficante DC; Hong H; Risech M; Lory S; Priebe GP
    Am J Respir Crit Care Med; 2012 Sep; 186(5):420-7. PubMed ID: 22723292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
    Pennington JE; Pier GB; Sadoff JC; Small GJ
    Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two Novel
    Zhao X; Dai Q; Jia R; Zhu D; Liu M; Wang M; Chen S; Sun K; Yang Q; Wu Y; Cheng A
    Front Cell Infect Microbiol; 2017; 7():391. PubMed ID: 28929089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
    Pennington JE; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An enterobacterial common antigen mutant of Salmonella enterica serovar Typhimurium as a vaccine candidate.
    Bridge DR; Whitmire JM; Gilbreath JJ; Metcalf ES; Merrell DS
    Int J Med Microbiol; 2015 Sep; 305(6):511-22. PubMed ID: 26070977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
    Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
    Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies.
    Stanislavsky ES; Joo I; Mashilova GM; Boolk VF; Boltutsy LG; Zakgeim DA; Severtśova MK; Yedvabnaya LS; Gladus MA; Fatkhinurova TI
    Vaccine; 1985 Jun; 3(2):128-36. PubMed ID: 3929491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice.
    Ohama M; Hiramatsu K; Miyajima Y; Kishi K; Nasu M; Kadota J
    FEMS Immunol Med Microbiol; 2006 Jun; 47(1):107-15. PubMed ID: 16706793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.
    Pier GB; Meluleni G; Goldberg JB
    Infect Immun; 1995 Aug; 63(8):2818-25. PubMed ID: 7542632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the abilities of Salmonella typhimurium rpoS, aroA and rpoS aroA strains to elicit humoral immune responses in BALB/c mice and to cause lethal infection in athymic BALB/c mice.
    Coynault C; Norel F
    Microb Pathog; 1999 Jun; 26(6):299-305. PubMed ID: 10343058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective efficacy afforded by live Pasteurella multocida vaccines in chickens is independent of lipopolysaccharide outer core structure.
    Harper M; John M; Edmunds M; Wright A; Ford M; Turni C; Blackall PJ; Cox A; Adler B; Boyce JD
    Vaccine; 2016 Mar; 34(14):1696-703. PubMed ID: 26892738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.